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ABSTRACT
Background: Depressive symptoms and impaired physical func-
tioning are prevalent among older adults. Supplementation with
vitamin D might improve both conditions, particularly in persons
with low vitamin D status.
Objective: The D-Vitaal study primarily aimed to investigate the
effect of vitamin D supplementation on depressive symptoms,
functional limitations, and physical performance in a high-risk older
population with low vitamin D status. Secondary aims included
examining the effect of vitamin D supplementation on anxiety
symptoms, cognitive functioning, mobility, handgrip strength, and
health-related quality of life.
Methods: This study was a randomized placebo-controlled trial with
155 participants aged 60–80 y who had clinically relevant depressive
symptoms, ≥1 functional limitations, and serum 25-hydroxyvitamin
D [25(OH)D] concentrations of 15–50/70 nmol/L (depending on
season). Participants received 1200 IU/d vitamin D3 (n = 77) or
placebo tablets (n = 78) for 12 mo. Serum 25(OH)D was measured
at baseline and 6 mo; outcomes were assessed at baseline, 6 mo, and
12 mo. Linear mixed-models analyses were conducted to assess the
effect of the intervention.
Results: The supplementation increased serum 25(OH)D concentra-
tions in the intervention group to a mean ± SD of 85 ± 16 nmol/L
compared with 43 ± 18 nmol/L in the placebo group after 6 mo
(P < 0.001). No relevant differences between the treatment
groups were observed regarding depressive symptoms, functional
limitations, physical performance, or any of the secondary outcomes.
Conclusions: Supplementation with 1200 IU/d vitamin D for 12 mo
had no effect on depressive symptoms and physical functioning in
older persons with relatively low vitamin D status, clinically relevant
depressive symptoms, and poor physical functioning. This trial is
registered with the Netherlands Trial Register (www.trialregister.nl)
under NTR3845. Am J Clin Nutr 2019;00:1–12.
Keywords: vitamin D, 25(OH)D, depressive symptoms, physical
functioning, functional limitations, physical performance, older
adults, randomized clinical trial, prevention, supplementation
Introduction
Depressive symptoms and poor physical functioning are 2
common and burdensome health conditions among older persons
(1–3). Simple and safe prevention strategies for these conditions
are lacking. In addition, the prevalence of inadequate vitamin D
status (serum 25-hydroxyvitamin D [25(OH)D] concentrations
<50 nmol/L) (4) is high in this population (5, 6).
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Previous research has suggested that low vitamin D status may
be associated with depressive symptoms as well as decreased
physical health, but the many studies in this field have often
yielded conflicting results. Although prospective cohort studies
suggest that lower vitamin D status is associated with more
depressive symptoms (7), functional limitations (8), and poorer
physical performance (9), evidence from randomized controlled
trials (RCTs) remains inconclusive regarding causality (10).
Biological evidence for the association of vitamin D
with depressive symptoms and poor physical functioning
is given by the presence of the activating enzyme 1α-
hydroxylase (CYP27B1)—which converts 25(OH)D into 1,25-
dihydroxyvitamin D [1,25(OH)2D]—and the vitamin D receptor
(VDR) in brain areas, such as the hippocampus, hypothalamus,
and cerebellum (11, 12), and the presence of 1,25(OH)2D and the
VDR in muscle cells (13). Furthermore, 1,25(OH)2D facilitates
the production of serotonin in the brain and has a general
protective and stimulating effect on brain and muscle tissue (12–
15), whereas severe vitamin D deficiency causes myopathy (16).
Additional evidence comes from studies with VDR knockout
mice: these rodents showed abnormal muscle development,
decreased muscle size and mass, altered grooming behavior, and
increased anxiety (16).
A review of 37 previous RCTs examining the effects of vitamin
D supplementation on depressive symptoms or physical func-
tioning concluded that the study designs were too heterogeneous
to draw conclusions (10). Supplementation dose, study duration,
and participant inclusion criteria differed substantially between
trials. Moreover, most of the previously conducted RCTs used
a general population sample, whereas it can be expected that
vitamin D supplementation is more effective and appropriate
for persons with insufficient 25(OH)D concentrations and actual
emotional and/or physical complaints. Furthermore, depressive
symptoms and physical problems are highly interrelated and
can reinforce each other (2, 3), which argues for a combined
approach. For these reasons, the present RCT was designed.
The D-Vitaal trial investigated whether vitamin D supplemen-
tation could improve depressive symptoms, functional limita-
tions, and physical performance in a high-risk older population
with relatively low vitaminD status, clinically relevant depressive
symptoms, and difficulties with physical functioning.
Methods
Study design
The D-Vitaal study is a randomized, double-blind, placebo-
controlled trial designed to investigate the effects of vitamin
D supplementation on depressive symptoms and physical func-
tioning in older adults. The design and methods have been
described elsewhere (10). The Medical Ethics Committee of
the VU University Medical Center approved the study, and all
participants provided written informed consent. The study is
registered with the Netherlands Trial Register as NTR3845.
Setting and participants
The study was performed in Amsterdam and surroundings
in the Netherlands from 2013 to 2016. Participants (n = 155)
were community-dwelling persons aged 60–80 y recruited from
the general population (81%) or through general practitioners
(19%). Inclusion criteria were presence of depressive symptoms
[as indicated by a Center of Epidemiological Studies–Depression
scale (CES-D) score of ≥16 (17)], ≥1 functional limitation (e.g.,
difficulties with walking, climbing stairs, or dressing oneself),
and a serum 25(OH)D concentration between 15 and 50 nmol/L
in winter (October–March) or between 15 and 70 nmol/L in
summer (April–September). These 25(OH)D cutoffs were based
on the study by van Schoor et al. (18) that showed that the
mean seasonal variation (winter–summer difference) of serum
25(OH)D in this age group is ∼20 nmol/L. This implies that
persons with serum 25(OH)D concentrations of <70 nmol/L in
summer will have inadequate vitamin D status (<50 nmol/L) in
winter. Persons with a current major depressive disorder (MDD)
diagnosis or life-threatening illness as well as persons currently
using antidepressant medication, vitamin D supplements of>400
IU/d, or calcium supplements of >1000 mg/d were excluded.
Randomization and blinding
All participants who fulfilled the inclusion criteria were
randomly allocated by an independent pharmacist in a 1:1 ratio
in blocks of 4 to receive either vitamin D or placebo.
Participants were stratified by sex, and women were further
stratified by age (60–70 y compared with 71–80 y), as we
expected to include more women than men in the study (19–
21). Participants, researchers, and research nurses were blinded
to group allocation during the study. Group assignment was
concealed until completion of the statistical analyses.
Intervention
The intervention consisted of a daily dose of 1200 IU vitamin
D3 (3 tablets of 400 IU cholecalciferol; Devaron) for 12 mo.
The placebo group received identical tablets without vitamin
D. All participants were allowed to take a (multi)vitamin D
supplement with a maximum of 400 IU/d in addition to the study
tablets. Furthermore, all participants were advised to use≥3 dairy
consumptions daily to ensure adequate calcium intake of ∼1000
mg/d. In case of <2 dairy consumptions per day, a calcium tablet
of 500 mg/d was prescribed for the duration of the study.
Outcomes and follow-up
Primary outcomes.
Primary outcomes of the D-Vitaal study were depressive
symptoms, functional limitations, and physical performance.
Depressive symptoms were assessed using the CES-D scale
(17). This scale consists of 20 items and ranges from 0 to 60, with
a higher score indicating more depressive symptoms. A score of
≥16 is indicative of clinically relevant depressive symptoms. This
outcome was defined as the difference in the 12-mo course of the
depressive symptoms score between the 2 treatment groups.
Functional limitations were assessed using the Longitudinal
Aging Study Amsterdam (LASA) Functional Limitations ques-
tionnaire (22). The participants were asked about their ability and
degree of difficulty to perform the following functions of daily
life: climbing stairs, cutting toenails, walking 5 min outdoors
without resting, rising from a chair, dressing/undressing oneself,
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and using own or public transport. Two scores can be derived
from this questionnaire: the number of functional limitations
(score 0–6) and the severity of functional limitations (score 0–
24). A higher score represents more functional limitations or
more severe functional limitations, respectively. These outcomes
were defined as the difference in the 12-mo course of the
functional limitation scores between the 2 treatment groups.
Physical performance was assessed using a modified version
of the Short Physical Performance Battery (SPPB) (9, 23). The
SPPB includes a walking test, a repeated chair stand test, and
a balance test. Participants could score 0–4 points on each test.
Total scores range from 0 to 12, with higher scores representing
better performance. This outcome was defined as the difference
in the 12-mo course of the physical performance score between
the 2 treatment groups.
Secondary outcomes.
Secondary outcomes included incidence of MDD, anxiety
symptoms, cognitive function, health-related quality of life (HR-
QoL), functional mobility, and muscle strength. In addition, we
analyzed depressive symptoms and the number of functional
limitations dichotomously.
The presence of MDD was assessed using the depression
section of the Composite International Diagnostic Interview
[version 2.1 (24)], which was administered only for CES-D
scores of ≥16. Anxiety was assessed using the Beck Anxiety
Inventory (BAI) (25). Cognitive function (i.e., information
processing speed and executive functioning) was assessed
using the Stroop Color-Word Test (26). HR-QoL was assessed
using the EuroQol-5 Dimensions (EQ-5D) (27) and the Short
Form–36 Health Survey (SF-36) (28). The timed up-and-go
(TUG) test (29) was assessed to test functional mobility.
Muscle strength was measured with a handgrip strength test
using a strain-gauged dynamometer (Takei TKK 5401; Takei
Scientific Instruments). Finally, in addition to the continuous
primary analyses, depressive symptoms and number of functional
limitations were analyzed dichotomously, with a CES-D cutoff
of 16 (presence compared with absence of clinically relevant
depressive symptoms) and a functional limitations cutoff of 1 (0
compared with ≥1 functional limitation).
Serum 25(OH)D measurements.
Serum 25(OH)D concentrations were measured at screen-
ing (baseline sample) and after 6 mo. Blood samples were
drawn in the morning by a trained research nurse. Mea-
surements were carried out using a well-standardized liq-
uid chromatography followed by tandem mass spectrometry
method (30, 31). Serum 25(OH)D concentrations at baseline
were determined immediately after blood draw, whereas the
6-mo samples were measured all at once at the end of the study to
ensure blinding. The 6-mo samples were stored at −80◦C, with
storage times until determination ranging from 6 to 27 mo.
Compliance.
Compliance was assessed by tablet count after 6 and 12
mo. A participant was considered compliant if ≥80% of the
tablets had been taken during the 12 mo of follow-up. In
addition, compliance of the participants in the intervention group
was indicated by their serum 25(OH)D concentrations after 6
mo of supplementation. If these concentrations had increased
by <10 nmol/L compared with baseline, and their 25(OH)D
concentration at 6 mo was <75 nmol/L, participants were also
considered noncompliant. During the study, compliance was
stimulated by contacting the participants at 2 wk, 3 mo, and
9 mo by telephone and by reminding them during follow-up
visits.
Adverse events.
Adverse events (AEs) were registered by telephone or face-to-
face contact after 2 wk and after 3, 6, 9, and 12 mo. If necessary,
the course of the AE was followed up by telephone.
Baseline characteristics and covariables.
Baseline characteristics included age, sex, season, marital
status, educational level, smoking (yes/no), alcohol use [cat-
egories according to the Garretsen index (32)], BMI, waist
and calf circumference, blood pressure and pulse rate, physical
activity, chronic diseases, medication and supplement use,
number of previous depressive episodes, use of psychological
counseling, and predictors of vitamin D (sunlight exposure, skin
pigmentation, fatty fish consumption).
Statistical analyses
Baseline characteristics were compared between the treatment
groups with Pearson χ2 tests (dichotomous or categorical
variables) or Mann-Whitney tests (skewed continuous variables).
Participants who dropped out were compared with participants
who completed the study with respect to age, sex, serum
25(OH)D, and the primary outcome variables. These differences
were tested with Mann-Whitney or Pearson χ2 tests.
Differences between treatment groups in the total number of
AEs were tested using a Mann-Whitney test, whereas group
differences with regard to categories of AEs were tested with
Pearson χ2 tests.
Alcohol consumption was dichotomized into no/mild/
moderate compared with (very) excessive alcohol use because
the treatment groups differed in the latter category.
To assess the effects of the intervention, linear mixed-model
analyses were conducted with the continuous primary and
secondary outcome scores at 6 and 12 mo as a longitudinal
outcome variable, treatment group as a fixed independent
variable, and the baseline value of the outcome as a fixed
covariate (model 1). In an additional model (model 2), we
adjusted for any potential confounding variable that differed
(P < 0.10) between treatment groups at baseline. We used an
unstructured covariance structure and added a random intercept
to the models to adjust for the dependency of the measures at 6
and 12 mo.
If the distribution of an outcome variable was skewed, a
natural logarithmic (ln) transformation was performed. If this
improved the distribution, analyses were conducted with the
transformed variable. To interpret the results of the analyses with
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logarithmically transformed outcome variables, the resulting B
values and CIs were transformed back. This back-transformation
changes the B value into a ratio, here representing the difference
between the intervention and placebo groups. For example, a ratio
of 1.05 should be interpreted as a 5% higher outcome score in the
intervention group compared with the placebo group.
Potential effect modification of age (continuous), sex, and
baseline serum 25(OH)D concentrations (dichotomous, cutoffs of
50 and 30 nmol/L) was examined in the crude models by adding
an interaction term (treatment× potential effect modifier). A time
interaction term (treatment group × time point) was added to
the crude models to investigate potential differences in effects
between 6 and 12 mo of follow-up. If an interaction term had
a P value of <0.10, stratified analyses were conducted. As the
study was not powered for stratified analyses, we emphasize that
these analyses are mainly exploratory.
Secondary dichotomous effect analyses for the CES-D score
and number of functional limitations were conducted with
general estimating equation analyses with an exchangeable
correlation structure. Models and effect modification methods
were similar to the continuous linear mixed-model analyses.
In preplanned sensitivity analyses, we examined whether
change in serum 25(OH)D was associated with parallel change
in the primary outcomes, irrespective of treatment group. For
these analyses, change scores were created for 25(OH)D and
the primary outcomes by calculating the difference between
the values at baseline and 6 mo. Subsequently, multiple linear
regression analyses were conducted with the change scores of
the primary outcomes as dependent variables, change in serum
25(OH)D as the independent variable, and the baseline values of
the independent and outcome variables as covariates. In a second
model, we also adjusted for age, sex, season, marital status (CES-
D analyses only), education level, alcohol use, smoking status,
physical activity, and number of chronic diseases.
The intention-to-treat (ITT) analyses included all participants
with ≥1 follow-up measurement. In the per-protocol effect
analyses, we excluded participants who were not compliant
according to the tablet count or otherwise not compliant with the
study protocol. All results are ITT results unless otherwise stated.
A double-sided P value of <0.05 was regarded as statistically
significant. IBMSPSS Statistics version 22 (SPSS, Inc.) was used
to perform all data analyses.
Power calculation
The statistical power analysis has been described in detail
elsewhere (10). In short, the power calculation was based
on the primary outcomes of depressive symptoms, functional
limitations, and physical performance. To calculate the number
of participants needed, a power of 80%, a 2-sided α of 0.05,
and an intraclass correlation coefficient of 0.70 between baseline
and follow-up measures were assumed. Based on a study with
similar sample characteristics (33), ≥40 participants per group
would be needed to detect a change of 0.5 SD (2.5 points)
on the CES-D. For the number of functional limitations, we
would need ≥28 participants per group to detect a meaningful
change of 1 point, assuming a SD of 1.7. Regarding the severity
of functional limitations, ≥48 participants per group would be
needed to detect a change of 2 points, assuming a SD of 4.5. For
physical performance, 22 persons per group would be needed to
detect a meaningful change of 1 point on the SPPB, assuming a
SD of 1.5. Taking into account an expected dropout of∼25% and
uncertainty of the 25(OH)D assay, ≥70 persons per group would
be needed, adding up to ≥140 participants.
Results
Participant characteristics
Figure 1 displays the participant flow of the D-Vitaal study.
We included 155 participants: 77 in the intervention group and
78 in the placebo group.
Baseline characteristics of the participants are presented
in Table 1. The placebo group contained more heavy drinkers
and current smokers than the intervention group. Participants
in the intervention and placebo groups were not different
regarding predictors of vitamin D status, use of vitamin D sup-
plements, or other baseline characteristics (data partly shown in
Table 1).
At baseline, 9 participants (5.8%) made use of any form of
psychological counseling: 5 in the intervention group and 4 in
the placebo group. Twenty-six participants (16.8%) started with
any form of psychological counseling during the study: 12 in
the intervention group and 14 in the placebo group (P for group
difference = 0.69). Furthermore, 5 participants (3.2%, 3 in the
intervention group and 2 in the placebo group) started with
antidepressant medication during the study.
Forty-four participants (18 in the intervention group and 26 in
the placebo group, P for group difference= 0.17) received a 500-
mg/d calcium supplement in addition to the study tablets because
they did not take ≥2 dairy consumptions per day [procedure as
described in the study protocol (10)].
Ten participants dropped out during the study: 3 in the inter-
vention group and 7 in the placebo group. Dropouts did not differ
significantly from participants who completed the study with
respect to age, sex, depressive symptoms, functional limitations,
or physical performance (all P > 0.05), but participants who
dropped out more often had serum 25(OH)D concentrations
<30 nmol/L (P = 0.034).
In total, only 151 of the 155 initially randomly assigned
participants could be included in the ITT analyses. Four
participants (2 in both groups) had to be excluded because of
insufficient data due to dropout shortly after the start of the study.
Therefore, we refer to these analyses as modified ITT analyses, as
not all initially randomly assigned participants could be included.
Compliance and serum 25(OH)D.
The average compliance according to tablet counts was 89.7%:
139 of 155 participants had a tablet intake of ≥80% throughout
the study year, similar in both groups (P for group difference =
0.30). Furthermore, 4 participants in the intervention group had a
<10-nmol/L increase in serum 25(OH)D in addition to a serum
25(OH)D concentration <75 nmol/L at 6 mo, which brings the
total compliance to 87.1%.
In the intervention group, the mean ± SD serum 25(OH)D
concentration after 6 mo of intervention was 85 ± 16 nmol/L
compared with 43 ± 18 nmol/L in the placebo group (P for
group difference < 0.001). The mean ± SD difference in
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Screening interview 
conducted:
n = 579
Excluded:
- CES-D <16 and/or no functional 
limitations: n = 1637
- use of >400 IU vitD: n = 54
- antidepressant use: n = 19
- withdrawn / lost to follow-up: n = 14
- deceased: n = 1
- other reason: n = 8
Excluded:
- 25(OH)D >50/70 nmol/L: n = 374
- 25(OH)D <15 nmol/L: n = 5
- CIDI score indicative of MDD: n = 32
- withdrawn / lost to follow-up: n = 8
- antidepressant use: n = 2
- use of >400 IU vitD: n = 2
- other reason: n = 1 Randomized: 
n = 155
Placebo: 
n = 78
Vitamin D3 1200
IU/day: n = 77
Included in 
intention-to-treat analyses: 
n = 75*
Included in 
intention-to-treat analyses: 
n = 76*
Dropout: n = 3
- deceased: n = 1
- perceived side effects: n = 2
Dropout: n = 7
- perceived side effects: n = 3
- no longer motivated / too 
burdensome: n = 4
Included in 
per-protocol analyses: 
n = 65**
Included in 
per-protocol analyses: 
n = 65***
Recruitment:
n ≈ 56,000
Screening questionnaire
returned:
n = 2312
FIGURE 1 Recruitment, selection, randomization, and follow-up of participants in the D-Vitaal study. ∗n= 2 excluded from the intention-to-treat analyses
due to insufficient data. ∗∗In the CES-D, BAI, SF-36 MCS, and EQ-5D analyses, an additional n = 2 were excluded completely, and the 12-mo measurements
were excluded for another n = 2. ∗∗∗In the CES-D, BAI, SF-36 MCS, and EQ-5D analyses, an additional n = 1 was excluded completely, and the 12-mo
measurements were excluded for another n = 3 in all per-protocol analyses. BAI, Beck Anxiety Inventory; CES-D, Center of Epidemiological Studies–
Depression scale; CIDI, Composite International Diagnostic Interview; EQ-5D, EuroQol-5 Dimensions; MDD, major depressive disorder; SF-36 MCS, Short
Form–36 Health Survey Mental Component Summary; vitD, vitamin D; 25(OH)D, 25-hydroxyvitamin D.
25(OH)D concentration after 6 mo compared with baseline was
40 ± 23 nmol/L for the intervention group compared with
−2 ± 20 nmol/L for the placebo group. After 6 mo, all
participants in the intervention group had reached serum
25(OH)D concentrations >50 nmol/L; 74.7% (n = 56) had
reached ≥75 nmol/L, and 29.3% (n = 22) had reached ≥90
nmol/L. In the placebo group, 35.1% (n = 26) had a serum
25(OH)D concentration>50 nmol/L after 6mo, 5.4% (n= 4) had
reached ≥75 nmol/L, and 25.7% (n = 19) had a serum 25(OH)D
concentration <30 nmol/L after 6 mo.
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TABLE 1 Baseline characteristics of the D-Vitaal participants1
Characteristic Intervention group (n = 77) Placebo group (n = 78)
Serum 25(OH)D,2 nmol/L 46 [32.5–57] 44 [36–55.25]
Baseline 25(OH)D <50 nmol/L3 47 (61.0) 52 (66.7)
Baseline 25(OH)D <30 nmol/L3 12 (15.6) 13 (16.7)
Age2 67.8 [65.4–71.7] 67.3 [63.4–72.0]
Women3 45 (58.4) 44 (56.4)
Season of baseline blood collection3
Winter 33 (42.9) 30 (38.5)
Summer 44 (57.1) 48 (61.5)
Marital status3
Never married/divorced 13 (16.9) 20 (26.0)
Married/living together/registered partner 49 (63.6) 46 (59.7)
Widowed 15 (19.5) 11 (14.3)
Education level3,4
Low 22 (29.3) 21 (26.9)
Intermediate 36 (48.0) 34 (43.6)
High 17 (22.7) 23 (29.5)
Alcohol consumption3,5#
None 17 (22.1) 12 (15.4)
Light 36 (46.8) 33 (42.3)
Moderate 21 (27.3) 20 (25.6)
(Very) excessive 3 (3.9) 13 (16.7)
Smoking3∗
No 70 (90.9) 59 (75.6)
Yes 7 (9.1) 19 (24.4)
BMI,2 kg/m2 27.1 [25.1–31.0] 26.9 [23.9–30.5]
Physical activity,2 kcal/d 509 [332–802] 494 [271–791]
Number of chronic diseases2 2 [1–2] 1 [1–2]
Number of medications2 4 [2–6] 4 [2–6]
Former depression3 34 (44.7) 34 (43.6)
Anxiety (BAI)2 10 [5–18] 11 [6–18.75]
Stroop test (interference score)2 17.5 [12–23] 18.5 [14–25.5]
Timed up-and-go test2 7 [6–8.75] 7 [6–8]
Handgrip strength2 27.1 [21.8–38.1] 26.1 [21.9–37.9]
SF-362
Physical functioning subscale 70 [50–85] 70 [45–85]
Physical component summary score 46.4 [40.8–52.1] 46.0 [42.2–49.1]
Mental component summary score 39.6 [33.3–43.8] 37.3 [33.6–41.3]
EQ-5D2
Index score 0.72 [0.65–0.84] 0.78 [0.69–0.84]
Visual analog scale 70 [50–80] 67 [50–75]
CES-D score2 22 [18–26.75] 21 [19–27]
Functional limitations2
Number 2 [0.25–4] 1.5 [0–3.25]
Severity 2 [0.25–4.75] 2 [0–5]
Physical performance (SPPB)2 8 [6–10] 8.5 [6.75–11.0]
1Values are displayed as n (%) or as median [IQR]. #P < 0.10. ∗P < 0.05. BAI, Beck Anxiety Inventory; CES-D, Center for Epidemiological
Studies–Depression scale; EQ-5D, EuroQoL-5 Dimensions; SF-36, Short Form–36 Health Survey; SPPB, Short Physical Performance Battery; 25(OH)D,
25-hydroxyvitamin D.
2Differences between treatment groups tested with Mann-Whitney test.
3Differences between treatment groups tested with Pearson χ2 test.
4Education level categories: low (less than elementary, elementary, or lower vocational education), intermediate (general intermediate, intermediate
vocational, or general secondary education), or high (higher vocational, college, or university education).
5Dichotomous analysis of alcohol use [no/mild/moderate compared with (very) excessive drinking]: P < 0.01.
AEs.
One participant in the intervention group died during the
study. No statistically significant differences were observed
between treatment groups with regard to the total number of AEs
(P = 0.24) or categories of AEs (all P > 0.05, Supplemental
Table 1).
Primary outcomes
As can be seen in Table 2 and Figure 2, depressive
symptoms and physical performance did not significantly
differ between the 2 treatment groups over 12 mo. All
interaction terms for these 2 outcomes were not significant
(P > 0.10).
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TABLE 2 Effect analyses of 12 mo of vitamin D supplementation compared with placebo on the primary and secondary outcomes (modified ITT)1
Crude model2 Adjusted model3
Characteristic n B/ratio 95% CI P B/ratio 95% CI P
Primary outcomes B B
Depressive symptoms (CES-D) 150 − 0.25 − 2.37, 1.87 0.82 − 0.14 − 2.36, 2.08 0.90
Functional limitations
Number 150 − 0.12 − 0.42, 0.18 0.42 − 0.11 − 0.42, 0.20 0.48
Baseline 25(OH)D <50 nmol/L 94 0.15 − 0.25, 0.54 0.46 0.22 − 0.20, 0.63 0.31
Baseline 25(OH)D ≥50 nmol/L 56 − 0.62 − 1.08, −0.17 0.008 − 0.65 − 1.11, −0.19 0.006
Severity 150 0.02 − 0.45, 0.50 0.93 − 0.03 − 0.52, 0.46 0.91
Baseline 25(OH)D <50 nmol/L 94 0.35 − 0.25, 0.96 0.25 0.30 − 0.35, 0.94 0.36
Baseline 25(OH)D ≥50 nmol/L 56 − 0.61 − 1.39, 0.18 0.13 − 0.64 − 1.44, 0.16 0.12
Physical performance (SPPB) 151 − 0.05 − 0.63, 0.54 0.88 − 0.20 − 0.79, 0.38 0.49
Secondary outcomes
Health-related quality of life B B
EQ-5D index score 150 − 0.02 − 0.07, 0.02 0.35 − 0.02 − 0.06, 0.03 0.52
Men 64 0.03 − 0.03, 0.10 0.31 0.03 − 0.04, 0.11 0.34
Women 86 − 0.06 − 0.12, −0.00 0.046 − 0.05 − 0.11, 0.01 0.11
EQ-5D visual analog scale 149 − 3.14 − 6.99, 0.72 0.11 − 3.31 − 7.32, 0.70 0.11
SF-36 Mental Component 148 − 0.31 − 2.01, 1.39 0.72 − 0.22 − 1.97, 1.54 0.81
SF-36 Physical Component 148 − 0.26 − 1.67, 1.14 0.71 − 0.22 − 1.67, 1.23 0.77
SF-36 Physical functioning subscale 140 0.32 − 3.79, 4.43 0.88 0.27 − 3.94, 4.48 0.90
Handgrip strength 150 − 0.56 − 1.66, 0.53 0.31 − 0.65 − 1.80, 0.50 0.27
Ratio Ratio
Anxiety symptoms (BAI)4 147 1.05 0.86, 1.27 0.65 1.03 0.84, 1.26 0.79
Cognitive function (Stroop test)4 146 0.98 0.86, 1.13 0.83 0.97 0.84, 1.12 0.67
Timed up-and-go test4 148 1.02 0.95, 1.08 0.63 1.03 0.97, 1.10 0.32
Younger-old group (60–70 y) 100 1.00 0.93, 1.08 0.99 1.03 0.95, 1.11 0.47
Older-old group (71–80 y) 48 1.02 0.92, 1.13 0.66 1.03 0.92, 1.14 0.62
1Linear mixed-model analyses. Explorative stratified analyses are italicized. Ps for interaction for the stratified analyses: number of functional
limitations: P = 0.020; severity of functional limitations: P = 0.084; EQ-5D index score: P = 0.041; timed up-and-go test: P = 0.087. BAI, Beck Anxiety
Inventory; CES-D, Center for Epidemiological Studies–Depression scale; EQ-5D, EuroQoL-5 Dimensions; ITT, intention to treat; SF-36, Short Form–36
Health Survey; SPPB, Short Physical Performance Battery.
2Adjusted for the baseline value of the outcome variable.
3Additionally adjusted for alcohol use and smoking.
4Analyzed with ln-transformed outcome variable, the Bs and 95% CIs were transformed back and should be interpreted as ratios, here representing the
difference between the intervention and placebo groups. For example, a ratio of 1.05 should be interpreted as a 5% higher outcome score in the intervention
group compared with the placebo group.
For both the number and severity of functional limitations,
the interaction term of serum 25(OH)D (cutoff of 50 nmol/L)
with treatment group was significant (P for interaction = 0.020
and 0.084, respectively), so the analyses for these outcomes
were stratified by baseline 25(OH)D concentration, with a cutoff
of 50 nmol/L. In the higher 25(OH)D group (≥50 nmol/L at
baseline), the intervention group experienced fewer functional
limitations compared with the placebo group over 12 mo, but
the difference in the severity of functional limitations between
the groups was not statistically significant. In the low 25(OH)D
group (<50 nmol/L at baseline), both the number and severity
of functional limitations did not differ significantly between the
treatment groups (Table 2).
Secondary outcomes
Five participants (3.4%) developed MDD according to the
Composite International Diagnostic Interview criteria in the
course of the study period: 3 in the intervention group and 2 in the
placebo group. Because of these low numbers, no further analyses
were conducted.
In the dichotomous CES-D analyses, the time interaction
term was significant (P for interaction = 0.072), indicating that
the effect of the intervention at 6 mo was different from the
effect at 12 mo. At 6 mo, more participants in the intervention
group scored below the cutoff (no clinically relevant depressive
symptoms) compared with the placebo group (55.6% compared
with 44.4%, P in adjusted model = 0.09), indicating that
the intervention group tended to experience fewer depressive
symptoms. However, at 12 mo, this difference was no longer
evident (48.8% compared with 51.3%, P in adjusted model =
0.63). The dichotomous analyses for the number of functional
limitations yielded similar results as the continuous analyses:
the P for interaction with baseline serum 25(OH)D was 0.056,
so stratified analyses were performed. In the group with serum
25(OH)D concentrations ≥50 nmol/L, the intervention group
more often had no functional limitations compared with the
placebo group (OR in adjusted model = 0.21; 95% CI: 0.05,
0.88; P = 0.032) over 12 mo, whereas there was no significant
difference between the treatment groups in the <50-nmol/L
group (OR in adjusted model = 1.92; 95% CI: 0.46, 8.04;
P = 0.37).
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FIGURE 2 Mean scores of the primary outcome variables over time for the intervention and placebo groups. The error bars represent SEMs. n per group:
(A) intervention: n = 75, placebo: n = 75; (B) intervention: n = 75, placebo: n = 76; (C) intervention: n = 30, placebo: n = 26; (D) intervention: n = 44,
placebo: n = 50. P for interaction for the stratified analyses of number of functional limitations: P = 0.020. BL, baseline; CES-D, Center of Epidemiological
Studies–Depression scale.
The analyses of the BAI anxiety questionnaire, Stroop test, and
TUG test were conducted with ln-transformed scores, as their
original distributions were skewed to the right. Significant effect
modifiers included sex for the EQ-5D index score analysis (P
for interaction = 0.041) and age in the TUG test analysis (P
for interaction = 0.087). Therefore, the analyses of the EQ-5D
index score were stratified for sex, and the TUG test analyses
were stratified for age (60–69 compared with 70–80 y).
As Table 2 shows, the treatment groups did not significantly
differ with regard to anxiety symptoms, cognitive functioning, the
TUG test, handgrip strength, the SF-36 HR-QoL measures, and
the EQ-5D Visual Analog Scale score over 12 mo (all P > 0.10).
Only the EQ-5D index score showed a significantly lower score
in women in the intervention group compared with women in the
placebo group, but this effect disappeared in the adjusted analyses
(Table 2).
Per-protocol analyses
Two data sets were created for the per-protocol analyses. In
the first per-protocol data set, 21 participants were excluded
completely for the following reasons: not compliant according to
tablet count (n = 16), <10-nmol/L increase of serum 25(OH)D
after 6 mo while being in the intervention group and having a
serum 25(OH)D <75 nmol/L after 6 mo (n = 4), or otherwise
not compliant with the study protocol (n = 1). For another 3
participants, only the 12-mo measurements were excluded due
to noncompliance with the study protocol between 6 and 12 mo.
This first data set was used to analyze all physical outcomes
and the Stroop test. The second data set was created for the per-
protocol analyses of the CES-D, BAI, SF-36 Mental Component
Summary, and EQ-5D. This second data set was similar to the
first data set, but an additional 3 participants were excluded
due to antidepressant medication use (n = 1) or baseline CES-
D scores below the inclusion cutoff (15 and 14, respectively,
n = 2). Furthermore, the 12-mo measurements of another 2
participants were excluded due to antidepressant medication use
between 6 and 12 mo in this second data set (the remaining 2 of 5
participants who started using antidepressant medication during
the study were already excluded due to noncompliance for other
reasons) (Figure 1).
All per-protocol analyses yielded results similar to the modi-
fied ITT analyses, although the effect of the supplementation on
the number of functional limitations in the 25(OH)D≥50-nmol/L
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group was somewhat attenuated (crude model: B = −0.51, 95%
CI: −0.98, −0.03, P = 0.036; adjusted model: B = −0.53, 95%
CI: −1.02, −0.03, P = 0.037).
Additional analyses
Six-month change in serum 25(OH)D, independent of group
assignment, was not significantly associated with parallel change
in the CES-D score (B in adjusted model: −0.01, SE: 0.03,
P = 0.73), functional limitations (number: B in adjusted model:
−0.001, SE: 0.003, P = 0.85; severity: B in adjusted model:
−0.004, SE: 0.01, P = 0.51), or physical performance (B in
adjusted model: −0.01, SE: 0.01, P = 0.32).
Discussion
The D-Vitaal study investigated whether vitamin D3 supple-
mentation of 1200 IU/d for 12 mo would improve depressive
symptoms, functional limitations, and physical performance in
older persons with relatively low vitamin D status, clinically
relevant depressive symptoms, and problems with physical
functioning. The supplementation increased serum 25(OH)D
concentrations in the intervention group to a mean of 85 nmol/L
after 6 mo, whereas the placebo group remained stable at a mean
of 43 nmol/L. However, the intervention had no significant effect
on depressive symptoms, physical performance, the severity of
functional limitations, or any of the secondary outcomes of
the study (anxiety symptoms, cognitive functioning, mobility,
grip strength, HR-QoL). Vitamin D supplementation had a
small positive effect on the number of functional limitations in
participants with serum 25(OH)D concentrations ≥50 nmol/L at
baseline.
Similar to our study, several other RCTs did not observe an
effect of vitamin D on depressive symptoms either (34–36). In
a recent trial, Jorde and Kubiak (37) compared 4 mo of 20,000
IU/wk vitamin D with placebo in 408 participants and found no
effect of the supplementation on the Beck Depression Inventory.
Baseline vitamin D status was <42 nmol/L, but relatively few
participants had depressive symptoms. Moreover, the authors
attributed positive findings from their previous RCTs on this topic
(38, 39) to chance. In contrast, 3 smaller trials that included per-
sons with both low vitamin D status and MDD did demonstrate a
reduction in depression after vitamin D supplementation (40–42).
These 3 studies included participants with a depression diagnosis,
as opposed to subthreshold depression in our trial, which may
explain the discrepancy in results.
Regarding the effect of vitamin D supplementation on physical
functioning, recent RCTs reported no effect on gait speed,
balance, physical performance, or muscle strength either (43–
45), even though these studies included participants with lower
vitamin D status and impaired physical functioning. On the
contrary, a study with postmenopausal women aged 50–65 y
with mean baseline 25(OH)D concentrations of 40 nmol/L and
a history of falling showed that 1000 IU/d for 9 mo had a positive
effect on lower extremity muscle strength and balance (46, 47).
Possibly, these differences between trial results can be attributed
to differences in measurement and sample characteristics.
There is a growing consensus that for many outcomes,
including depression and physical functioning, supplementation
with vitamin D is beneficial only in persons with low serum
25(OH)D concentrations (<50 nmol/L) (48–50). In an extensive
review of trial data, Rejnmark et al. (51) evaluated the current
evidence regarding the extraskeletal effects of vitamin D and
noted that most studies were conducted with persons with replete
25(OH)D concentrations, which may explain the null findings of
many trials. Nevertheless, the D-Vitaal study shows the absence
of an effect of vitamin D supplementation in a high-risk sample
with relatively low vitamin D status.
The small but statistically significant positive effect of the
intervention on the number of functional limitations in the
group with baseline 25(OH)D concentrations ≥50 nmol/L was
surprising. We expected an effect of the supplementation on the
outcomes to be more pronounced in persons with the lowest
baseline 25(OH)D concentrations. Furthermore, the≥50-nmol/L
group did not reach higher 25(OH)D concentrations after 6 mo
compared with the<50-nmol/L group. We therefore believe that,
besides not being clinically relevant (52), this effect is most likely
a chance finding. Furthermore, our study was not specifically
powered for stratified analyses, so these analyses were mainly
exploratory.
Strengths of the D-Vitaal study include the double-blind,
randomized, placebo-controlled design, with inclusion of persons
hypothesized to optimally benefit from the supplementation:
an older population with depressive symptoms, poor physical
functioning, and relatively low vitamin D status. Dropout was
relatively low (6.5%), and compliance was high (87%). To
examine the effects of the intervention, we used longitudinal
statistical techniques to make optimal use of the available data.
A potential limitation of the present study is the relatively small
n of 155 persons, although this number was sufficient according
to the power calculation (10). Nevertheless, considering the
small effect sizes, it is doubtful that a larger sample size would
have yielded different results. Another potential limitation is
that we included participants with a maximum serum 25(OH)D
concentration of 70 nmol/L in summer. In winter, the limit was
set to 50 nmol/L.We checked for interaction effects with baseline
25(OH)D (cutoffs of 50 and 30 nmol/L), but the group with
<30 nmol/L at baseline may have been too small to detect
an interaction effect. It is possible that our inclusion criteria
regarding serum 25(OH)D were too liberal. Potentially, a limit
of <50 nmol/L in summer and <30 nmol/L in winter would
yield different results, but this would also complicate recruitment
considerably. As an additional explorative analysis, we tested
whether analyses stratified at a baseline serum 25(OH)D of 30
nmol/L would show a different picture for the primary outcomes,
even though the interaction effect was not statistically significant.
However, all results were nonsignificant (data not shown), but
due to the small n in the <30-nmol/L group, the validity of these
results is uncertain.
Presence of MDD and use of antidepressant medication were
exclusion criteria in our study; we included only persons with
subthreshold depression (CES-D ≥16). Therefore, we may have
included persons who had only short-lived symptoms at the time
of inclusion and improved naturally over time. This could explain
the drop in CES-D scores in both groups between baseline and
6 mo (Figure 2A). However, the mean CES-D score remained
around 16 in both groups at 6 and 12 mo, demonstrating that
a substantial proportion of participants had clinically relevant
depressive symptoms throughout the study period.
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcn/article-abstract/doi/10.1093/ajcn/nqz141/5537848/ by Sussex Language Institute user on 08 O
ctober 2019
10 de Koning et al.
Compared with other supplementation trials, our vitamin D
dose of 1200 IU/d is relatively low. Nevertheless, participants
in the intervention group were replete at 6 mo, with a mean
25(OH)D concentration of 85 nmol/L. As serum 25(OH)D
concentrations tend to reach a plateau after a few months of
supplementation (53), similar concentrations are assumed after
12 mo. Recent research indicates that higher doses are not more
effective and can even be harmful, for instance, by increasing the
number of falls or reducing muscle strength (50, 54, 55).
It is remarkable that observational studies have demonstrated
rather consistent associations between vitamin D status and
numerous health outcomes, whereas this is often not confirmed
by trial evidence (56, 57). Therefore, it is more likely that vitamin
D status is a marker for poor health or inflammation instead of a
cause of disease (58).
At the moment, several large-scale, long-term RCTs are being
conducted to examine the effects of vitamin D supplementation
onmultiple outcomes in older persons: theVitaminDAssessment
Study (ViDa) trial (n = 5110, 100,000 IU/mo for a median
period of 3.3 y) (59), the VITamin D and OmegA-3 (VITAL) trial
and its ancillary the VITamin D and OmegA-3 Trial–Depression
Endpoint Prevention (VITAL–DEP) study (n = 25,874, 2000
IU/d for a mean period of 5 y) (60, 61), and the Vitamin
D3–Omega3–Home Exercise –HeALTHy Ageing and Longevity
Trial (DO-HEALTH) (n = 2152, 2000 IU/d for 3 y) (62).
Although these trials use general population samples, the n is
large enough to allow for subgroup analyses. The outcomes of
these trials will shed more light on the complex relationship of
vitamin D with depression and physical functioning. In addition,
theremay be some potential in the combination of antidepressants
with vitamin D in the treatment of depression (63), although a
recent report suggests that it can be challenging to conduct such
an RCT (64).
The D-Vitaal recruitment phase was also challenging. We
had to send out ∼56,000 information brochures to include 155
participants, which underlines the difficulty of recruiting for this
type of RCT in the general population. Most of the potential
participants did not respond to our invitation, which might
have been due to ineligibility or lack of interest to participate
in an RCT. Including participants with even lower baseline
serum 25(OH)D concentrations (<30 nmol/L) would be of great
scientific interest but will be complicated to accomplish, both
ethically and practically.
Based on the results of this study, supplementation with
vitamin D for the prevention of depression and poor physical
functioning cannot be recommended. However, it is important
to continue research for effective and acceptable prevention
strategies for these health problems in older persons.
In conclusion, this randomized placebo-controlled trial found
no effect of 1200 IU/d vitamin D supplementation for 1 y
on depressive symptoms or physical functioning in a high-risk
population with relatively low vitamin D status.
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